# Research Handoff Note: NSCLC Precision Oncology Evidence (Step 7)

This document provides a reviewed summary of literature evidence and molecular context, along with unresolved claims and human-review checklists, regarding precision oncology for Non-Small-Cell Lung Cancer (NSCLC).

---

## 1. Problem Statement and Scope

### Objective
To synthesize a reviewable evidence table for literature-backed claims about NSCLC precision oncology, specifically separating verified clinical treatment-efficacy evidence from biological/molecular-context evidence and model speculations. 

### Scope
* **Disease Scope**: Non-small-cell lung cancer (NSCLC), focusing on lung adenocarcinoma, advanced, or metastatic disease.
* **Genes**: *EGFR*, *ALK*, and *TP53*.
* **Drugs / Interventions**: Osimertinib, crizotinib, standard EGFR-TKIs (gefitinib/erlotinib/afatinib), and pemetrexed-plus-platinum chemotherapy.

---

## 2. Search Strategy, Query Scope, and Stopping Rule

### Search Strategy and Query Scope
Searches were conducted on the PubMed database using progressive, single-variable query adjustments. The scope of queries ranged from a broad concept intersection to highly targeted searches for clinical trials and prognostic biomarkers:
1. **Broad Concept Intersection**: NSCLC AND (*EGFR* OR *ALK* OR *TP53*) AND (osimertinib OR crizotinib OR pemetrexed).
2. **EGFR/Osimertinib Focus**: NSCLC AND *EGFR* AND osimertinib AND RCT/clinical trial filters.
3. **ALK/Crizotinib Focus**: NSCLC AND *ALK* AND crizotinib AND RCT/clinical trial filters.
4. **TP53 Focus**: NSCLC AND *TP53* AND (*EGFR* OR *ALK*) AND prognosis/survival/resistance filters.
5. **Chemotherapy Backbone Focus**: NSCLC AND pemetrexed AND platinum (cisplatin/carboplatin) AND trial filters.
6. **Double-Driver Focus**: NSCLC AND *EGFR* AND *ALK* AND osimertinib AND crizotinib.

### Stopping Rule
The search was terminated when:
1. Subsequent searches (such as Run 6) returned zero new clinical trials or prospective cohorts comparing the target therapies.
2. The comparison of osimertinib vs. crizotinib in concurrent *EGFR*-mutated and *ALK*-rearranged patients was determined to have no randomized trial data. The search stopped, and the claim was cataloged as `not_found`.

---

## 3. Reviewed Evidence Summary

This summary includes only claims verified in the [evidence_table.demo.csv](file:///Users/godkin/Projects/LLM_applications_on_BioMedicalData/demos/lesson-04-literature-evidence-workflow/evidence_table.demo.csv) and is separated strictly by classification:

### A. Literature Evidence (Treatment-Efficacy)

* **Osimertinib vs. Standard EGFR-TKIs (First-Line)**: First-line osimertinib significantly prolongs progression-free survival (PFS) compared to standard EGFR-TKIs (gefitinib or erlotinib) in untreated advanced *EGFR*-mutated NSCLC (Median PFS: 18.9 months vs. 10.2 months; HR: 0.46; $P<0.001$). **[Row 1, PMID: 29151359, DOI: 10.1056/NEJMoa1713137]**
* **Chemotherapy + Osimertinib (First-Line)**: Combining pemetrexed-plus-platinum chemotherapy with first-line osimertinib significantly improves progression-free survival compared to osimertinib monotherapy in advanced *EGFR*-mutated NSCLC (Investigator-assessed PFS HR: 0.62; $P<0.001$). **[Row 2, PMID: 37937763, DOI: 10.1056/NEJMoa2306434]**
* **Adjuvant Osimertinib (Stage IB-IIIA)**: Adjuvant osimertinib provides a significant disease-free survival (DFS) benefit over placebo in patients with completely resected stage IB-IIIA *EGFR*-mutated NSCLC (DFS HR: 0.27; 4-year DFS rate: 73% vs. 38%). **[Row 3, PMID: 36720083, DOI: 10.1200/JCO.22.02186]**
* **Osimertinib after Chemoradiotherapy (Stage III)**: Osimertinib consolidation significantly improves progression-free survival compared to placebo in patients with unresectable stage III *EGFR*-mutated NSCLC who did not progress during or after chemoradiotherapy (Median PFS: 39.1 months vs. 5.6 months; HR: 0.16; $P<0.001$). **[Row 4, PMID: 38828946, DOI: 10.1056/NEJMoa2402614]**
* **Amivantamab + Chemotherapy after Osimertinib Progression**: Amivantamab plus carboplatin-pemetrexed chemotherapy (with or without lazertinib) significantly prolongs PFS compared to chemotherapy alone in patients with *EGFR*-mutated advanced NSCLC after progression on osimertinib (PFS HR: 0.48 and 0.44, respectively; $P<0.001$ for both). **[Row 5, PMID: 37879444, DOI: 10.1016/j.annonc.2023.10.117]**
* **First-Line Lorlatinib vs. Crizotinib (Initial Analysis)**: First-line lorlatinib treatment leads to significantly higher 12-month PFS (78% vs. 39%; HR: 0.28; $P<0.001$) compared to crizotinib in advanced *ALK*-positive NSCLC. **[Row 6, PMID: 33207094, DOI: 10.1056/NEJMoa2027187]**
* **First-Line Lorlatinib vs. Crizotinib (5-Year Update)**: Long-term 5-year follow-up confirms that first-line lorlatinib maintains superior PFS compared to crizotinib (Median PFS: not reached vs. 9.1 months; HR: 0.19) in advanced *ALK*-positive NSCLC. **[Row 7, PMID: 38819031, DOI: 10.1200/JCO.24.00581]**
* **First-Line Alectinib vs. Crizotinib**: Alectinib shows superior progression-free survival (HR: 0.47; $P<0.001$) and lower toxicity compared to crizotinib in previously untreated advanced *ALK*-positive NSCLC. **[Row 8, PMID: 28586279, DOI: 10.1056/NEJMoa1704795]**
* **Amivantamab-Lazertinib vs. Osimertinib in TP53 Co-mutated Subgroup**: First-line amivantamab-lazertinib significantly improves progression-free survival compared to osimertinib monotherapy in patients with *EGFR*-mutated advanced NSCLC harboring *TP53* co-mutations (Median PFS: 18.2 months vs. 12.9 months; HR: 0.65; $P=0.003$). **[Row 10, PMID: 38942080, DOI: 10.1016/j.annonc.2024.05.541]**
* **Pemetrexed-plus-Platinum Chemotherapy Backbone**: Pemetrexed-plus-platinum chemotherapy represents a standard first-line treatment option for patients with metastatic nonsquamous NSCLC without *EGFR* / *ALK* alterations (placebo plus chemotherapy arm yielding a 5-year OS rate of 11.3%). **[Row 12, PMID: 36809080, DOI: 10.1200/JCO.22.01989]**

### B. Molecular Context (Prognosis, Clonality, and Biology)

* **Prognostic Impact of TP53 Mutations in ALK-positive Disease**: Detectable baseline *TP53* mutations in plasma cell-free DNA are associated with poor progression-free survival in patients with advanced *ALK*-positive NSCLC receiving ALK-TKIs (crizotinib or brigatinib). **[Row 9, PMID: 34537440, DOI: 10.1016/j.jtho.2021.07.035]**
* **Clonal Nature of Driver Mutations**: Driver mutations in *EGFR* and *TP53* are clonal events arising early in the evolutionary history of NSCLC and are highly stable across regions in early-stage tumors. **[Row 11, PMID: 28445112, DOI: 10.1056/NEJMoa1616288]**
* **Prognostic Impact of TP53 Mutations in EGFR-mutated Disease**: In patients with *EGFR*-mutated advanced NSCLC, the presence of baseline *TP53* co-mutations is associated with a poor prognosis (shorter response/PFS) when treated with first-line EGFR-TKIs. **[Row 13, PMID: 38942080, DOI: 10.1016/j.annonc.2024.05.541]**

---

## 4. Unresolved Claims

* **Model Inference (Speculation)**: It is hypothesized that *TP53* mutations directly upregulate alternative bypass pathway signaling (such as MET or HER2) to mediate acquired resistance to osimertinib in *EGFR*-mutant NSCLC. This bypass pathway hypothesis is biologically plausible but not directly supported by clinical data in our current verified inventory. **[Row 14, model_inference]**
* **Not Found**: Efficacy comparison of crizotinib versus osimertinib in patients with advanced NSCLC harboring both *EGFR* mutations and *ALK* rearrangements. No clinical trials or prospective cohorts comparing these TKIs in double-driver patients were found due to the extreme rarity of concurrent alterations. **[Row 15, not_found]**
* **Conflicting**: None.
* **Not Accessible**: None.

---

## 5. Human-Review Decisions and Remaining Limitations

### Review Decisions
* All 15 rows in the evidence table remain marked as `needs_human_review = TRUE` to indicate that clinical/expert confirmation is mandatory before translation into clinical templates.
* Biomarker subgroup analyses with unreported sample sizes (e.g., *TP53* cohort sizes in ALTA-1L and MARIPOSA abstracts) have been explicitly kept as `UNKNOWN` rather than estimated.

### Remaining Limitations
1. **Abstract-Level Extraction**: Efficacy subgroup sizes (especially for genetic subsets like *TP53* co-mutated cohorts) are frequently omitted from PubMed abstracts, restricting the completeness of the database extraction without full-text access.
2. **Survival Data Maturity**: Several trials (e.g., LAURA, FLAURA2, MARIPOSA) have immature overall survival (OS) data, meaning that claims are currently heavily reliant on progression-free survival (PFS) endpoints.
3. **Comparator Evolution**: First-generation comparators (such as crizotinib for *ALK* or gefitinib/erlotinib for *EGFR*) are rapidly being replaced by newer generation inhibitors in standard first-line guidelines.

---

## 6. Next Actions

For the unresolved claims, the following next steps are scheduled:

1. **Investigate acquired resistance mechanisms to osimertinib (Row 14 - `model_inference`)**:
   * *Next Action*: Perform a PubMed search with: `("osimertinib resistance"[tiab] AND "TP53"[tiab] AND ("MET amplification"[tiab] OR "HER2"[tiab]))`.
   * *Objective*: Identify in vitro or clinical cohort evidence linking *TP53* co-mutations to specific bypass pathways.
   * *Target Date*: 2026-07-12.

2. **Investigate double-driver EGFR+/ALK+ therapy outcomes (Row 15 - `not_found`)**:
   * *Next Action*: Perform a PubMed search with: `("EGFR mutation"[tiab] AND "ALK rearrangement"[tiab] AND ("osimertinib"[tiab] OR "crizotinib"[ti] OR "case report"[tiab]))`.
   * *Objective*: Retrieve retrospective case reports or case series to document clinical management and responses in this rare population.
   * *Target Date*: 2026-07-12.
